Clinical Trial Update: A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB [Phase 1, Phase 2]

View source ↗

Summary

Phase I dose-finding and safety study of LDE225 (sonidegib) in children with recurrent or refractory medulloblastoma, with a Phase II portion to assess prelimin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioma
• Hepatoblastoma
• Medulloblastoma
• Neuroblastoma
• Rhabdomyosarcoma

Drugs mentioned

• LDE225 (sonidegib) (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Medulloblastoma, Rhabdomyosarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-03-02